Asyikeen Wan Adnan Wan Nor, Siti-Azrin Ab Hamid, Jalil Nur Asyilla Che, Zin Anani Aila Mat, Othman Nor Hayati
Unit of Biostatistics and Research Methodology, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia.
Department of Pathology, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia.
Malays J Med Sci. 2016 Nov;23(6):44-51. doi: 10.21315/mjms2016.23.6.5. Epub 2016 Dec 7.
Endometrial cancer is the most common gynaecologic malignancy among females worldwide. The purpose of this study was to determine the median survival time of endometrial cancer patients at the Hospital Universiti Sains Malaysia (USM).
A list of 121 endometrial cancer cases registered at Hospital USM between 2000 until 2011 was retrospectively reviewed. The survival time of the endometrial cancer patients was estimated by Kaplan-Meier survival analysis. Log-rank tests were performed to compare the survival of the patients based on socio-demographics and clinical presentation.
Only 108 patients, 87.0%, were included who were of Malay ethnicity. Previous history included menopause in 67.6% of patients and diabetes mellitus in 39.8% of patients; additionally, 63.4% of patients were nulliparous. Tumour staging was as follows: 24.5% stage I, 10.8% stage II, 26.5% stage III and 38.2% stage IV. The overall median survival time of the endometrial cancer patients was 70.20 months (95% confidence interval (CI): 51.79, 88.61). The significant factors were age, the presence of lymphovascular invasion and treatment received.
The overall survival of endometrial cancer was low. A prospective study needs to be carried out to discover more effective and accurate tests for the early detection of endometrial cancer.
子宫内膜癌是全球女性中最常见的妇科恶性肿瘤。本研究的目的是确定马来西亚理科大学医院（USM）子宫内膜癌患者的中位生存时间。
回顾性分析了2000年至2011年在USM医院登记的121例子宫内膜癌病例。通过Kaplan-Meier生存分析估计子宫内膜癌患者的生存时间。进行对数秩检验以比较基于社会人口统计学和临床表现的患者生存率。
仅纳入了108例患者（87.0%），均为马来族。既往史包括67.6%的患者有绝经史，39.8%的患者有糖尿病史；此外，63.4%的患者未生育。肿瘤分期如下：I期24.5%，II期10.8%，III期26.5%，IV期38.2%。子宫内膜癌患者的总体中位生存时间为70.20个月（95%置信区间（CI）：51.79，88.61）。显著因素为年龄、是否存在淋巴管浸润以及接受的治疗。
子宫内膜癌的总体生存率较低。需要开展前瞻性研究以发现更有效、准确的早期检测子宫内膜癌的检查方法。
